Menin-MLL inhibitor-22

Menin-MLL inhibitor-22 (compound C20) is an orally active inhibitor of the interaction between menin and mixed lineage leukemia (MLL) (IC50=7 nM) . Menin-MLL inhibitor-22 binds menin protein and inhibits cancer cell growth (MV4 cells, IC50=0.3 μM) . Menin is a putative tumor suppressor associated with multiple endocrine neoplasia type 1 (MEN-1 syndrome) [1].

Product Specifications

CAS Number

[2851841-61-5]

UNSPSC

12352005

Target

Epigenetic Reader Domain

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/menin-mll-inhibitor-22.html

Purity

99.85

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=S(C1=CC=C(N2CC(CN3CCC(NC4=NC=NC5=CC=C(N=C54)OCCN(C)C)CC3)C2)C=C1)(C6CC6)=O

Molecular Formula

C29H39N7O3S

Molecular Weight

565.73

References & Citations

[1]Lei H, et al. Discovery of Novel, Potent, and Selective Small-Molecule Menin-Mixed Lineage Leukemia Interaction Inhibitors through Attempting Introduction of Hydrophilic Groups. J Med Chem. 2022 Oct 13;65 (19) :13413-13435.